Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $ ...
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $48.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback